Case Report: Favorable Response and Manageable Toxicity to the Combination of Camrelizumab, Oxaliplatin, and Oral S-1 in a Patient With Advanced Epstein–Barr Virus-Associated Gastric Cancer

Some pertinent studies have demonstrated that Epstein–Barr virus-associated gastric cancer (EBVaGC) patients showed a favorable clinical outcome to immunotherapy and Epstein–Barr virus (EBV)-positive status might be a potential biomarker for immunotherapy in gastric cancer (GC). However, knowledge o...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, Wanrui, Cheng, Ke, Li, Xiaofen, Feng, Lusi, Li, Hancong, Li, Jia, Chang, Chen, Cao, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791849/
https://www.ncbi.nlm.nih.gov/pubmed/35096571
http://dx.doi.org/10.3389/fonc.2021.759652

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791849/
https://www.ncbi.nlm.nih.gov/pubmed/35096571
http://dx.doi.org/10.3389/fonc.2021.759652

Ejemplares similares